Search

Your search keyword '"Arantxa González"' showing total 251 results

Search Constraints

Start Over You searched for: Author "Arantxa González" Remove constraint Author: "Arantxa González"
251 results on '"Arantxa González"'

Search Results

1. Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials

2. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

3. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial

4. ADAMTSL3 knock-out mice develop cardiac dysfunction and dilatation with increased TGFβ signalling after pressure overload

5. Identification of sex‐specific biomarkers predicting new‐onset heart failure

6. Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance

7. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

8. Generation of NKX2.5GFP Reporter Human iPSCs and Differentiation Into Functional Cardiac Fibroblasts

9. Evaluation of miCRovascular rarefaction in vascUlar Cognitive Impairment and heArt faiLure (CRUCIAL): Study protocol for an observational study

10. A Urinary Fragment of Mucin-1 Subunit α Is a Novel Biomarker Associated With Renal Dysfunction in the General Population

11. Circulating Biomarkers Predicting Longitudinal Changes in Left Ventricular Structure and Function in a General Population

12. The Role of Circulating Biomarkers in Peripheral Arterial Disease

13. Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population.

14. Prediction of Left Ventricular Reverse Remodeling and Outcomes by Circulating Collagen-Derived Peptides

15. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

16. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

17. Cardiac remodelling - Part 2

18. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study

19. Urinary Proteomic Signature of Mineralocorticoid Receptor Antagonism by Spironolactone: Evidence from the Randomized-Controlled HOMAGE and PRIORITY Trials

20. Single-cell analysis of the long noncoding RNA transcriptome in cardiac fibroblasts identifies FIXER, a novel therapeutic target for fibrosis in the damaged heart

21. Exercise training-induced changes in exerkine concentrations may be relevant to the metabolic control of type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials

22. Endotrophin, a Collagen VI Formation–Derived Peptide, in Heart Failure

24. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology

25. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF

26. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2?

27. The Myocardium in Aortic Stenosis Revisited

28. Interacción cardiorrenal y evolución de la insuficiencia cardiaca. ¿Tiene un papel la proteína de unión del factor de crecimiento de tipo insulina 2?

29. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure

30. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action

31. La fibrosis intersticial miocárdica en la era de la medicina de precisión. El fenotipado basado en biomarcadores para un tratamiento personalizado

32. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial

33. Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology

34. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

35. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

36. Revisiting skeletal myopathy and exercise training in heart failure: Emerging role of myokines

37. Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

39. Combination of Circulating Type I Collagen-Related Biomarkers Is Associated With Atrial Fibrillation

40. Analysis of the pilot survey INKLUGI about aging and disabilities to promote Inclusive Design in industry

41. CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation

42. MO734CONTRIBUTION OF SOLUBLE ST2 TO THE EFFECT OF RIGHT VENTRICULAR DYSFUNCTION ON MORTALITY IN HEMODIALYSIS PATIENTS

43. Deficiency of Procollagen C-Proteinase Enhancer 1 in Mice has No Major Impact on Cardiac Collagen and Function Under Basal Conditions

44. Urinary peptides in heart failure: a link to molecular pathophysiology

45. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial

46. The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

47. COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology

48. Serum and urinary biomarkers of collagen type‐I turnover predict prognosis in patients with heart failure

49. The combination of carboxy-terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic dilated cardiomyopathy - A multilevel assessment of myocardial fibrosis in dilated cardiomyopathy

50. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches

Catalog

Books, media, physical & digital resources